Restricted accessResearch articleFirst published online 2017-08
An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation
In advanced and metastatic stages of colorectal cancer (CRC), reduced sensitivity to conventional strategies is still a major obstacle to successful treatments. Decorin is an important regulator in the development and progression of various cancers. To examine if CRC patients have altered decorin levels, expression of decorin and its target genes, Met and vascular endothelial growth factor A (VEGFA), were analyzed in their tumors. Compared to normal tissues, decorin expression was reduced in CRC patients' tumors, while there were increased Met and VEGFA levels. To develop a novel therapy for CRC, rAd.DCN.GM, an oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor (GM-CSF), has been created. Several therapeutic strategies expressing GM-CSF have been employed in clinical trials for treating metastatic colorectal cancer. In this study, infection of CRC cells with rAd.DCN.GM expressed decorin and GM-CSF, and produced cytotoxicity. In murine CT26 xenografts, rAd.DCN.GM and control adenoviruses were administrated intratumorally on days 7 and 10, and tumor volumes were monitored over time. The study showed that rAd.DCN.GM inhibited the tumor growth and lung metastases significantly. rAd.DCN.GM induced apoptosis, inhibited proliferation, and downregulated angiogenesis and epithelial mesenchymal transition markers in the tumors. On day 12 and day 29, the immune-activation in the peripheral blood, tumors, and spleens were analyzed. rAd.DCN.GM increased CD8+ T lymphocytes in the blood, upregulated perforin and granzyme B in the tumors, inhibited transforming growth factor beta expression, and promoted dendritic-cell production in the spleen. In conclusion, rAd.DCN.GM inhibited the tumor growth and metastasis of CT26 tumors, downregulated multiple pro-tumorigenic pathways, and activated antitumor immune responses.
Get full access to this article
View all access options for this article.
References
1.
CenterMM, JemalA, SmithRA, et al.Worldwide variations in colorectal cancer. CA Cancer J Clin, 2009; 59:366–378.
2.
National Cancer Institute. SEER cancer statistics factsheets: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html (last accessed February12, 2017).
3.
American Cancer Society. Colorectal cancer facts and figures 2014–2016. Atlanta, GA: American Cancer Society, 2014.
4.
Gonzalez-PonsM, Cruz-CorreaM. Colorectal cancer biomarkers: where are we now?. Biomed Res Int, 2015; 2015:149014.
5.
SunJ, ZhangS, JiangS, et al.Gadolinium-loaded solid lipid nanoparticles as a tumor-absorbable contrast agent for early diagnosis of colorectal tumors using magnetic resonance colonography. J Biomed Nanotechnol, 2016; 12:1709–1723.
6.
WangY, CostanzaF, LiC, et al.PEG-poly (amino acid) s/microRNA complex nanoparticles effectively arrest the growth and metastasis of colorectal cancer. J Biomed Nanotechnol, 2016; 12:1510–1519.
7.
LuoM, LiangX, LuoST, et al.Folate-modified lipoplexes delivering the interleukin-12 gene for targeting colon cancer immunogene therapy. J Biomed Nanotechnol, 2015; 11:2011–2023.
8.
SunQ, ChenX, ZhouQ, et al.Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct Target Ther, 2016; 1:16010.
9.
RiesSJ, BrandtsCH, ChungAS, et al.Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med, 2000; 6:1128–1133.
10.
KaufmanHL, BinesSD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol, 2010; 6:941–949.
11.
HeoJ, ReidT, RuoL, et al.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med, 2013; 19:329–336.
12.
WierdaWG, CastroJE, AguillonR, et al.A Phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia, 2010; 24:1893–1900.
13.
AndtbackaRH, RossM, PuzanovI, et al.Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM Phase III clinical trial. Ann Surg Oncol, 2016; 23:4169–4177.
14.
PohA. First oncolytic viral therapy for melanoma. Cancer Discov, 2016; 6:6.
15.
HuZB, WuCT, WangH, et al.A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Cancer Gene Ther, 2008; 15:173–182.
16.
XuW, ZhangZ, YangY, et al.Ad5/48 hexon oncolytic virus expressing sTGFbetaRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases. Mol Ther, 2014; 22:1504–1517.
17.
YangY, XuW, NeillT, et al.Systemic delivery of an oncolytic adenovirus expressing decorin for the treatment of breast cancer bone metastases. Hum Gene Ther, 2015; 26:813–825.
18.
XuW, NeillT, YangY, et al.The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther, 2015; 22:247–256.
19.
IozzoRV, SchaeferL. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol, 2015; 42:11–55.
20.
NeillT, PainterH, BuraschiS, et al.Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J Biol Chem, 2012; 287:5492–5506.
21.
YamaguchiY, MannDM, RuoslahtiE. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature, 1990; 346:281–284.
22.
NymanMC, SainioAO, PennanenMM, et al.Decorin in human colon cancer: localization in vivo and effect on cancer cell behavior in vitro. J Histochem Cytochem, 2015; 63:710–720.
23.
SantraM, SkorskiT, CalabrettaB, et al.De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A, 1995; 92:7016–7020.
24.
ChoiIK, LeeYS, YooJY, et al.Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther, 2010; 17:190–201.
BramanteS, KaufmannJK, VeckmanV, et al.Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Int J Cancer, 2015; 137:1775–1783.
27.
ParkSH, BreitbachCJ, LeeJ, et al.Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer. Mol Ther, 2015; 23:1532–1540.
28.
ZhengL, EdilBH, SoaresKC, et al.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol, 2014; 21:3931–3937.
29.
CorrealeP, BottaC, RotundoMS, et al.Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized Phase III trial. J Immunother, 2014; 37:26–35.
30.
MorseMA, NiedzwieckiD, MarshallJL, et al.A randomized Phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg, 2013; 258:879–886.
31.
HuZ, GuptaJ, ZhangZ, et al.Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-beta inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther, 2012; 23:871–882.
32.
HuZ, GersenyH, ZhangZ, et al.Oncolytic adenovirus expressing soluble TGFbeta receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther, 2011; 19:1609–1618.
33.
KatayoseD, GudasJ, NguyenH, et al.Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res, 1995; 1:889–897.
34.
EdwardsIJ. Proteoglycans in prostate cancer. Nat Rev Urol, 2012; 9:196–206.
35.
NashMA, DeaversMT, FreedmanRS. The expression of decorin in human ovarian tumors. Clin Cancer Res, 2002; 8:1754–1760.
36.
TroupS, NjueC, KliewerEV, et al.Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res, 2003; 9:207–214.
KazandjianD, SuzmanDL, BlumenthalG, et al.FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist, 2016; 21:634–642.
42.
JurczakW, BrykAH, MensahP, et al.Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report. J Med Case Rep, 2016; 10:123.
43.
ZhangW, WangY, GuoY, et al.Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early Phase IIa trial report. Signal Transduct Target Ther, 2016; 1:16002.
44.
RankiT, PesonenS, HemminkiA, et al.Phase I study with ONCOS-102 for the treatment of solid tumors—an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer, 2016; 4:17.
45.
WorkenheST, MossmanKL. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy. Oncoimmunology, 2013; 2:e27138.
46.
DraperSJ, HeeneyJL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol, 2010; 8:62–73.
47.
MajhenD, CalderonH, ChandraN, et al.Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field. Hum Gene Ther, 2014; 25:301–317.
48.
Sofeu FeugaingDD, GotteM, ViolaM. More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol, 2013; 92:1–11.
49.
XuY, XiaQ, RaoQ, et al.DCN deficiency promotes renal cell carcinoma growth and metastasis through downregulation of P21 and E-cadherin. Tumour Biol, 2016; 37:5171–5183.
50.
BiX, PohlNM, QianZ, et al.Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis, 2012; 33:326–330.
51.
JungB, StaudacherJJ, BeauchampD. Transforming growth factor beta superfamily signaling in development of colorectal cancer. Gastroenterology, 2017; 152:36–52.
52.
ZhuH, LuoH, ShenZ, et al.Transforming growth factor-beta1 in carcinogenesis, progression, and therapy in cervical cancer. Tumour Biol, 2016; 37:7075–7083.
FlavellRA, SanjabiS, WrzesinskiSH, et al.The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol, 2010; 10:554–567.
55.
MarcoeJP, LimJR, SchaubertKL, et al.TGF-beta is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol, 2012; 13:843–850.
56.
NymanJS, MerkelAR, UppugantiS, et al.Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone, 2016; 91:81–91.
57.
RodonJ, CarducciM, Sepulveda-SanchezJM, et al.Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in Phase 1 study in patients with advanced cancer. Investig New Drugs, 2015; 33:357–370.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
